A Phase I, Randomised, Double-Blind, Placebo-Controlled, Single Centre, 3-Part, Study Designed to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of Single and Multiple Ascending Doses of GDC-0334 and the Effect of Food on the Pharmacokinetics of GDC-0334 in Healthy Adult Subjects
Phase of Trial: Phase I
Latest Information Update: 27 Jun 2019
Price : $35 *
At a glance
- Drugs GDC-0334 (Primary)
- Indications Inflammation
- Focus Adverse reactions; Therapeutic Use
- Sponsors Genentech
- 24 Jun 2019 Status changed from recruiting to discontinued.
- 10 Oct 2018 Planned End Date changed from 15 May 2019 to 3 Jul 2019.
- 10 Oct 2018 Planned primary completion date changed from 15 May 2019 to 3 Jul 2019.